Catapult Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Catapult Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$254K	Buy	+30,000	New	+$508K	0.1%	143

Other funds holding PETX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Catapult Capital Management's PETX Position: Q3 2015 in Review

Catapult Capital Management opened a new position in Aratana Therapeutics, Inc. (PETX) in Q3 2015: 30,000 shares worth $254K. The stake represents 0.1% of the portfolio and ranks #143 among its holdings.

103 funds tracked by Wall St. Rank hold PETX as of Q3 2015.

Catapult Capital Management held 30,000 shares of Aratana Therapeutics, Inc. worth $254K as of Q3 2015.
Aratana Therapeutics, Inc. was a new Catapult Capital Management position in Q3 2015.
Aratana Therapeutics, Inc. made up 0.1% of Catapult Capital Management's portfolio in Q3 2015, its #143 holding.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.